Table 2.
Closed/Suspended Hsp90 Inhibitor Clinical Trials
| Inhibitor | Combined Drug | Phase | Sponsor | Indication* |
|---|---|---|---|---|
| Tanespimycin (KOS-953) | Bortezomib | II/III | BMS | Relapsed/refractory MM |
| Tanespimycin (KOS-953) | Bortezomib | III | BMS | MM in first relapse |
| 17-AAG | - | II | NCI | Stage III or IV melanoma |
| 17-AAG | - | II | NCI | Von Hippel-Lindau disease and renal tumors |
| 17-AAG | - | II | NCI | Metastatic papillary or clear cell RCC |
| 17-AAG | - | II | NCI | Refractory locally advanced or metastatic breast cancer |
| 17-AAG | - | II | NCI | Metastatic malignant melanoma |
| 17-AAG | - | II | NCI | Inoperable locoregionally advanced or metastatic medullary or differentiated thyroid carcinoma |
| 17-AAG | - | II | NCI | Hormone-refractory metastatic prostate cancer |
| 17-AAG | - | II | NCI | Relapsed or refractory anaplastic large cell lymphoma, MCL, or classical Hodgkin’s lymphoma |
| 17-AAG | - | II | NCI | Systemic mastocytosis |
| 17-AAG | - | I | Other** | Advanced malignancies |
| 17-AAG | - | I | NCI | Refractory or advanced solid tumors or hematologic malignancies |
| 17-AAG | - | I | NCI | Unresectable solid tumors or relapsed lymphoma |
| 17-AAG | - | I | NCI | Advanced epithelial cancer, malignant lymphoma, or sarcoma |
| 17-AAG | - | I | NCI | Advanced solid tumors |
| 17-AAG | - | I | NCI | Recurrent or refractory leukemia or selected solid tumors |
| 17-AAG | - | I | NCI | Imatinib mesylate-resistant chronic phase CML |
| 17-AAG | - | I | NCI | Metastatic or unresectable solid tumors or lymphoma |
| 17-AAG | Docetaxel | I | NCI | Progressive metastatic prostate cancer or other progressive metastatic or unresectable solid tumors |
| 17-AAG | Imatinib | I | NCI | CML |
| 17-AAG | - | I | NCI | Pediatric patients with relapsed or refractory solid tumors or leukemia |
| 17-AAG | Paclitaxel | I | NCI | Metastatic or unresectable solid malignancy |
| 17-AAG | Cytarabine | I | NCI | Relapsed or refractory AML, ALL, CML, CMML, or high-grade MDS |
| 17-AAG | w/wo Rituximab | I | NCI | Relapsed B-cell chronic lymphocytic leukemia or prolymphocytic leukemia |
| 17-AAG | Bortezomib | I | NCI | Relapsed or refractory AML, ALL, CLL, or NHL |
| 17-AAG | Irinotecan | I | NCI | Locally advanced or metastatic solid tumors |
| 17-AAG | Sorafenib | I | NCI | Metastatic or unresectable solid tumors |
| 17-DMAG | - | I | NCI | Advanced solid tumor or lymphoma |
| 17-DMAG | - | I | NCI | Metastatic or unresectable solid tumors or lymphomas |
| 17-DMAG | - | I | NCI | Metastatic or unresectable solid tumors |
| 17-DMAG | I | NCI | Unresectable or metastatic solid tumors | |
| IPI-504 | - | III | Infinity | Metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib |
| IPI-504 | - | I/II | Infinity | Relapsed/refractory stage IIIb, or stage IV NSCLC |
| IPI-504 | - | II | Infinity | Hormone-resistant prostate cancer |
| IPI-504 | - | I | Infinity | Relapsed and relapsed refractory MM |
| IPI-504 | - | I | Infinity | GIST or STS |
| IPI-504 | Trastuzumab | II | Infinity | Pretreated, locally advanced or metastatic HER2 positive breast cancer |
| IPI-504 | Docetaxel | I | Infinity | Advanced solid tumors |
| BIIB021 | - | I | Biogen Idec | Advanced solid tumors |
*
multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), mantle cell lymphoma (MCL), metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), gastrointestinal stromal tumor (GIST), non-Hodgkin’s lymphoma (NHL), soft tissue sarcoma (STS), renal cell carcinoma (RCC)
**
Cancer Research UK Clinical Groups at Guy’s, King’s & St. Thomas’ Hospitals.